FY20 Results and Strategy Overview

Private large portfolio companies EXTERNALLY VALUED ӨӨ 08 RETAIL (PHARMACY) BUSINESS OVERVIEW (CONT'D) Margin enhancement and strong growth in para-pharmacy sales Strong sales in para-pharmacy products of GEL 186.3 million in 2020 (up 29.7% y-o-y), with 31.4% gross profit margin. Para-pharmacy sales have the strongest margins and the share of para-pharmacy sales in retail revenue reached 34.7% in 2020 (31.0% in 2019). FY20 CASH FLOW HIGHLIGHTS GEORGIA CAPITAL REVENUE Gross profit margin (%) 24.5% 25.5% 25.5% 25.4% 26.0% 24.2% AVERAGE BILL SIZE & NUMBER OF BILLS ISSUED Number of bills issued, million 25.3 27.1 28.8 27.6 +10.5% Same store growth (%) NMF 9% 9% 6% 800 679.4 614.7 GEL million 600 518.6 184.7 450.3 176.9 +16.4% 134.5 400 113.9 GEL 16.8 14.3 13.3 13.4 201.0 494.7 172.7 200 437.8 336.4 384.1 58.7 49.7 123.0 142.3 0 2017 2018 2019 2020 4Q19 4Q20 ■Retail Distribution Number of pharmacies countrywide 255 270 296 309 EBITDA¹ 2017 2018 2019 CUSTOMER INTERACTIONS PER MONTH GEL 66.1m +24.4% y-o-y Operating leverage¹(%) Operating cash flow¹ NMF 7.8% 4.1% -1.4% 4.1% -1.9% c.0.8mln EBITDA margin¹ (%) 93.9% 8.6% 10.1% 10.6% 10.4% 11.1% 10.1% Loyal customers +12.5ppts y-o-y EBITDA to cash conversion¹ GEL 60.8m +27.7% y-o-y Free cash flow¹ Georgia Capital PLC | 1. Excluding IFRS16 impact GEL million 150 100 +7.8% 70.4 65.3 52.2 38.9 50 +6.0% 19.2 20.3 million 20 10 2020 2.1 2.3 2.4 2.3 0 0 2017 2018 2019 2020 4Q19 4Q20 2017 2018 2019 2020 50

View entire presentation